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and 1970s the nurse practitioner became a new professional in the USA 
by reason of shortage of primary care physicians. Van Offenbeek et al 
(2003) described the effects of the embedding of the nurse practitioner 
in the health system in the Netherlands. The main part of the role of 
the nurse practitioner was the coordination of patient care, performing 
medical acts, consultation and keeping medical consulting hours. In ad-
dition, the role of the nurse practitioner seemed particularly suitable to 
integrate the nursing and medical and social aspects of patient care.
Only in 1997, the ﬁrst nurse practitioner education in the Netherlands 
was established, and in 2001 the Netherlands Cancer Institute-Antoni 
van Leeuwenhoek Hospital appointed its ﬁrst nurse practitioner. The 
nurse practitioner thorax oncology started in February 2004. 
The nurse practitioner is a member of the thoracic oncology group, 
consisting of dedicated (radiation) oncologists and surgeons. He 
integrates different roles; nursing care, expert, consultant, education, 
research and nursing leadership. This focusses on particular prob-
lems seem in lung cancer and mesothelioma patients. He forms a link 
between outpatient clinic and clinical care, performing all medical 
actions that are written in dedicated protocols and consulting medical 
specialists for situations that go beyond the protocols. He prescribes 
medication under supervision of medical specialists. He is especially 
equiped to integrate complex medical-social problems and counseling 
for patients and their families. In the clinic, he educates and supports 
the nursing staff conserning speciﬁc lung cancer related issues, like 
nebulization and pleural ﬂuid drainage. He is actively involved in 
medical research, e.g. setting-up the study logistics, informing and sup-
porting patients in the study. 
Conclusion: The nurse practitioner is a fairly new profession in the 
Netherlands Cancer Institute. This profession creates a good balance 
between nursing care and medical care. From the patient’s point of 
view it is important that the integrated care is given by one profession-
al. He is allowed to prescribing medication, although political debate 
on this problem is still ongoing.
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Background: Management of patients with lung cancer requires the 
involvement of multiple specialists. A multidisciplinary approach to 
care is advocated to facilitate shared-decision making which can im-
prove the quality of care. Setting up multidisciplinary clinics is difﬁcult 
because of the number of different specialists needed and their widely 
disparate work schedules. A multidisciplinary thoracic oncology con-
ference (MD-TOC) involving the key specialists is potentially a way of 
achieving the beneﬁts of multidisciplinary care. However, the effective-
ness of this approach depends on compliance with recommendations. 
We report our experience with patients presented to a new MD-TOC at 
the Methodist University Hospital, Memphis TN, a tertiary healthcare 
teaching facility in the USA. The period of analysis spans the time from 
inauguration of the conference in February 2006 to January 2007. 
Methods: Descriptive retrospective comparison of MD-TOC recom-
mendations and actual clinical management of consecutive patients. 
MD-TOC participants included a thoracic surgeon, pulmonologist, 
medical oncologist, radiation oncologist, pathologist and radiolo-
gist. Actual clinical management information was obtained from an 
electronic medical record system at the University of Tennessee Cancer 
Institute. MD-TOC recommendations were obtained from meeting 
logs. This study was approved by the Institutional Review Board of the 
University of Tennessee.
Results: Fifty two patients were presented, 28 females and 24 males, 
median age was 63 years (range 43 to 77). The patients were repre-
sentative of an urban population in the southern US, with 35 African 
American, 14 caucasian, 2 hispanic and 1 native American. Employ-
ment status was as follows: 6 employed, 13 unemployed, 16 retired, 
3 disabled, 13 unknown, 1 prison inmate. The health care payor 
characteristics were as follows: 21 with commercial insurance, 6 with 
medicare 6; 3 with medicaid 3; 20 with no insurance, 1 unknown and 1 
‘other’.
Nine of 52 patients had no diagnosed cancer: 2 expired before biopsy, 2 
had benign lung lesions, 3 refused biopsy and 2 were lost to followup. 
Forty-three patients (82.7%) were diagnosed with cancer with the fol-
lowing histology: adenocarcinoma 21 (49%), squamous cell 16 (37%), 
small cell 4 (9%), large cell neuroendocrine 1 (2%), bronchoalveolar 
cell carcinoma 1 (2%). Five of 43 patients (11.6%) were not clinically 
staged: 3 declined evaluation, 1 failed to followup, 1 patient was treated 
with chemotherapy without documented staging. Thirty-eight patients 
were clinically staged as follows: stage I, 6 (15.8%); II, 1 (2.6%); IIIA, 
6 (15.8%); IIIB, 12 (31.6%); IV, 13 (34.2%).
MDTOC recommendations and clinical concordance were as follows: 
18 patients were recommended for an invasive procedure, which was 
performed in 9 (50%). Nine of 18 patients (2 for surgical resection, 4 
for staging percutaneous CT-guided biopsy, 3 for staging mediastinos-
copy) did not undergo the recommended surgical procedure. Three of 
these nine patients declined the recommended procedure and received 
no treatment, 6 of 9 patients were treated with chemotherapy and/or 
radiation therapy without the recommended procedure. Of the 31 
patients for whom chemotherapy was recommended, 30 received treat-
ment, 1 patient declined and was lost to followup. Radiation therapy 
was recommended for 16 patients, all of whom received that modality 
of treatment. Participation in a clinical trial was recommended for 5 
patients, none participated.
Conclusions: There is a high level of concordance with non-surgical 
treatment recommendations of an MD-TOC, but relatively poor con-
cordance with recommendations for invasive staging procedures and 
surgical management. The reasons for this include patient and provider 
dissent. The multi-disciplinary thoracic oncology clinic environment, 
with active patient participation, may be a better model to ensure bet-
ter concordance with evidence-based recommendations and clinical 
practice.
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Background: The objective of this study was to identify which symp-
toms commonly associated with advanced non-small-cell lung cancer 
(NSCLC) are most likely to change (worsen or improve) in association 
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with clinical events (disease progression or tumor response) or changes 
in patient functioning (i.e., performance status). 
Methods: Eighty patients with advanced NSCLC (median age = 70.5 
years) were prospectively studied during the ﬁrst 12 weeks of their che-
motherapy. Eligibility criteria included diagnosis of new or recurrent 
stage III or IV NSCLC, initiation of chemotherapy (any line), over age 
18, comprehension of English, and no substantial cognitive or physi-
cal impairments. Symptoms were assessed weekly through telephone 
administration of the Functional Assessment of Cancer Therapy Lung 
Symptom Index-12 (FLSI-12), a brief, reliable and valid symptom 
measure for advanced lung cancer, with items scaled from 0 (not at 
all) to 4 (very much). Based on FLSI-12 item scores, all patients were 
at least slightly symptomatic at baseline. Data on Eastern Cooperative 
Oncology Group performance status (PS) were collected from patients 
every three weeks during clinic visits. At baseline, most patients (83%) 
rated themselves PS 0 (normal activity) or PS 1 (symptomatic, fully 
ambulatory). Symptom reports were mapped onto on-study clinical 
events (progression or response) and PS assessments. Disease progres-
sion and tumor response were determined by clinicians from radiologi-
cal evidence using RECIST criteria. 
Results: Several symptoms worsened in association with disease 
progression and declining PS. Disease and chemotherapy-related 
symptoms, such as, pain, shortness of breath, cough, weight loss and 
appetite loss worsened most with disease progression. Patients respond-
ing to chemotherapy reported more fatigue and difﬁculty breathing 
at response than immediately before it. However, unlike the patients 
who progressed, patients responding to chemotherapy never or rarely 
complained of pain, weight loss, cough, chest tightness, nausea, or 
confusion before, during, or after response. Symptoms most associated 
with changes in PS were fatigue, weight loss, nausea, and appetite loss. 
For these, declining PS was associated with considerably more symp-
tom worsening than unchanged or improving PS. However, pulmo-
nary symptoms (shortness of breath, cough, chest tightness, difﬁculty 
breathing) were less clearly associated with changes in PS. 
Conclusions: This study provides some direction that pulmonary 
symptoms and other general symptoms such as pain, loss of appetite 
and weight loss are most closely associated with disease progression. 
Patients responding to chemotherapy are less likely to have worsening 
of their pulmonary symptoms. A larger study may deﬁnitively identify 
changes in disease symptoms associated with disease progression and 
overall survival. Such information could assist clinicians in monitoring 
patient status on treatment and possibly investigate and modify treat-
ment depending on changes in symptom proﬁle.
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Background: Some factors such as age, stage and PS may provide 
prognostic information in advanced NSCLC; however, a better un-
derstanding of a patient’s judgement can help the Physician to make 
appropriate decisions. 
Purpose: 1- To study the information provided by pts in a question-
naire. 2 To study PS evolution obtained by the doctor (DPS) and by 
the pts themselves (PPS).3-To evaluate the correlation between some 
different variables with survival.
Patients and Method: 248 pts with stages III and IV NSCLC, age 
range 38 - 74 years, were studied. The study was prospective. Pts un-
derwent chemotherapy and/ or radiotherapy. They determined their own 
PS through a questionnaire. Some different variables such as age, stage, 
DPS, PSP, appetite, food intake, amount of solid food, evening meals, 
average meal per day, serving size, vomiting frequency, daily work 
activity, activity restrictions, and hours of rest per day were analyzed. 
DPS and PPS were studied at diagnosis and at 3 months. Statistical 
methods: Cox Proportional-Hazards Regression, Chi Square Pearson, 
Irwin-Fisher, Wilcoxon tests and Kaplan Meier Curves were used.
Results: According to the univariate logrank test applied to the com-
parison of the Kaplan and Meier survival curves, many factors seem to 
be related to survival.The correlation among predictor variables is not 
taken into account when using the univariate approach, so a Cox model 
for the proportional risk was ﬁtted using all the predictor variables 
available. A stepwise model selection was applied. It was found that 
only initial WL and DPS at the third month of evaluation were posi-
tively related to the risk of death. 
Conclusion: Although the univariate approach showed that many 
factors are related to the survival of patients, the simultaneous analysis 
of these factors through the Cox model revealed that few of them sum-
marize the most relevant prognostic information. These variables are 
DPS at the third month of evaluation and initial WL.
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Objectives: NGO’s are close to rural coomunities than City-based 
hospitals. Cost of running a NGO far less than medical institution. Cost 
of anti-ancer drugs is debatable at many forums. Pharma co’s dont give 
substantial discounts to patients. In resource poor setting unafford-
able cost leads to poor therapeutic compliance & high mortality. This 
Cost hurdle was overcome using our Community-NGO based model. 
It provides cost-effective methodology. We need to establish com-
mon strategy to develop of sound & sustainable cancer care programs 
avaialble to rural communities
Methods: Our NGO volunteers have strength of 24. cost of chemo-Ra-
dio therapy is beyond reach of common people in developing nations. 
Chemotherapy treatment in ci6ty speciality hospitals is unaffordable. 
No national program for ﬁnancial help to lung cancer patients avail-
able. Some NGO’s’s do offer little psychosocial support & subsidised 
treatment options. But such efforts are not cohesive. I lead team to con-
duct small seminars to mobilise community NGO’s support for Lung 
cancer patients. We work for 10 hours per week free of cost to help 
poor patients for treatment access [illeterate poor patients from villeges 
need guidance & little ﬁnacial help]. Depending on support given by 
corporates & few local donors we give these poor people little ﬁnancial 
assistance to cover treatment cost. We help these patients in getting 
access to governmental hospitals, till today our NGO covered 9 villages 
supporting 64 lung cancer sufferers. 
Results: We did face hiccups in mobilising volunteers & resources. We 
now have ﬁve local community NGO’s integrated program. These can-
